Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 4.8% Higher

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)’s stock price shot up 4.8% on Tuesday . The company traded as high as $14.24 and last traded at $14.23. 87,013 shares changed hands during trading, a decline of 89% from the average session volume of 826,571 shares. The stock had previously closed at $13.58.

Analysts Set New Price Targets

A number of equities analysts have commented on ZNTL shares. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush increased their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $38.57.

Zentalis Pharmaceuticals Stock Up 3.8 %

The company has a 50 day moving average price of $13.40 and a 200-day moving average price of $14.98. The company has a market cap of $1.12 billion, a P/E ratio of -3.35 and a beta of 1.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. On average, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Melissa B. Epperly sold 2,573 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares of the company’s stock, valued at $5,164,576.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE lifted its position in shares of Zentalis Pharmaceuticals by 88.7% during the 2nd quarter. US Bancorp DE now owns 887 shares of the company’s stock valued at $25,000 after acquiring an additional 417 shares during the last quarter. Captrust Financial Advisors boosted its stake in Zentalis Pharmaceuticals by 15,160.0% in the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after purchasing an additional 758 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Zentalis Pharmaceuticals by 132.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock worth $36,000 after purchasing an additional 1,030 shares in the last quarter. Quest Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $38,000. Finally, Tower Research Capital LLC TRC increased its holdings in Zentalis Pharmaceuticals by 252.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after buying an additional 2,589 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.